Delay PAH progression to stay ahead
How can UPTRAVI help?
UPTRAVI® (selexipag) is a prescription medicine for PAH (WHO Group 1). It is used to treat the high blood pressure in the arteries of your lungs. Since PAH is a progressive disease, it can get worse over time. The goal of treatment with UPTRAVI is to help delay (slow down) PAH progression to stay ahead.1
In a clinical study of UPTRAVI, PAH disease progression was defined as a serious event, such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy; lung transplantation; or a decline in 6-minute walk distance (6MWD) combined with worsening of functional class (FC) or need for additional PAH therapy; or death.